State-Level History of Overdose Deaths Involving Stimulants in the United States, 1999‒2020.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Source:
      Publisher: American Public Health Association Country of Publication: United States NLM ID: 1254074 Publication Model: Print Cited Medium: Internet ISSN: 1541-0048 (Electronic) Linking ISSN: 00900036 NLM ISO Abbreviation: Am J Public Health Subsets: MEDLINE
    • Publication Information:
      Publication: Washington, DC : American Public Health Association
      Original Publication: New York [etc.]
    • Subject Terms:
    • Abstract:
      Objectives. To examine the state-level history of US overdose deaths involving stimulants with and without opioids from 1999 to 2020. Methods. We used death certificate data from the National Center for Health Statistics to categorize deaths into 4 groups of interest: cocaine with and without opioids, and psychostimulants with and without opioids. We used a Bayesian multiple change point model to describe the timing and magnitude of changes in overdose death rates involving stimulants for each state and year. Results. There was little change in the death rates of cocaine without opioids. Death rates involving cocaine and opioids sharply increased around 2015, particularly in the Northeast and Mid-Atlantic. We also observed steady increases in deaths involving psychostimulants without opioids just before 2010, particularly in states in the West and South. Deaths involving psychostimulants with opioids increased around 2015 with largest increases concentrated in Appalachian states. Conclusions. There is significant geographic heterogeneity in the co-involvement of stimulants in the US overdose crisis. Results can inform public health efforts to inform state-level overdose efforts such as naloxone distribution. ( Am J Public Health. 2023;113(9):991-999. https://doi.org/10.2105/AJPH.2023.307337).
    • Comments:
      Comment in: Am J Public Health. 2023 Sep;113(9):933-935. doi: 10.2105/AJPH.2023.307379. (PMID: 37556788)
    • References:
      Int J Drug Policy. 2019 Aug;70:40-46. (PMID: 31079029)
      Epidemiol Rev. 2020 Jan 31;42(1):154-166. (PMID: 33511987)
      Drug Test Anal. 2022 Mar;14(3):416-426. (PMID: 34708938)
      Natl Vital Stat Rep. 2019 Oct;68(12):1-16. (PMID: 32501207)
      MMWR Morb Mortal Wkly Rep. 2020 Mar 27;69(12):317-323. (PMID: 32214077)
      J Clin Pharm Ther. 2021 Oct;46(5):1189-1193. (PMID: 33460173)
      NCHS Data Brief. 2021 Apr;(406):1-8. (PMID: 33814035)
      MMWR Morb Mortal Wkly Rep. 2019 Aug 30;68(34):737-744. (PMID: 31465320)
      Addict Behav. 2019 Mar;90:250-257. (PMID: 30471553)
      MMWR Morb Mortal Wkly Rep. 2021 Feb 12;70(6):202-207. (PMID: 33571180)
      MMWR Morb Mortal Wkly Rep. 2018 Jan 04;67(5152):1419-1427. (PMID: 30605448)
      Drug Alcohol Depend. 2020 Aug 1;213:108089. (PMID: 32531703)
      MMWR Morb Mortal Wkly Rep. 2020 Sep 04;69(35):1189-1197. (PMID: 32881854)
      Fed Regist. 2006 Sep 26;71(186):56008-27. (PMID: 17017470)
      MMWR Morb Mortal Wkly Rep. 2020 Aug 21;69(33):1117-1121. (PMID: 32817603)
      Curr Opin Psychiatry. 2021 Jul 1;34(4):344-350. (PMID: 33965972)
      Addiction. 2020 May;115(5):946-958. (PMID: 31912625)
      Soc Sci Med. 2023 Jan;317:115525. (PMID: 36493502)
    • Grant Information:
      K01 DA053435 United States DA NIDA NIH HHS; K01 DA055758 United States DA NIDA NIH HHS; R01 DA052214 United States DA NIDA NIH HHS; R25 DA037190 United States DA NIDA NIH HHS
    • Accession Number:
      0 (Analgesics, Opioid)
      0 (Central Nervous System Stimulants)
      I5Y540LHVR (Cocaine)
    • Publication Date:
      Date Created: 20230809 Date Completed: 20230811 Latest Revision: 20240902
    • Publication Date:
      20240902
    • Accession Number:
      PMC10413741
    • Accession Number:
      10.2105/AJPH.2023.307337
    • Accession Number:
      37556789